What Clinical Trials Show on Prolia Duration
Prolia (denosumab) trials lasted up to 10 years for postmenopausal osteoporosis, with no new fractures after 3 years and stable bone density.[1] A 3-year FREEDOM extension study found continued benefits but rising vertebral fracture risk after stopping without follow-up therapy.[2]
Recommended Treatment Length by Guidelines
Endocrine Society guidelines suggest 3-5 years for most postmenopausal women, then reassess fracture risk via DXA scan and markers like CTX or PINP.[3] Beyond 5 years, benefits diminish while risks grow, so many switch to bisphosphonates.
Risks of Long-Term Use Beyond 5 Years
After 3 years, risks include osteonecrosis of the jaw (0.04-0.1% cumulative), atypical femoral fractures (0.1% per 100 patient-years after 3 years), and severe hypocalcemia.[4][1] Multiple vertebral fractures occur in 50% of patients stopping after 3 years without bisphosphonate bridging.[2]
What Happens If You Stop Prolia Suddenly
Rebound bone loss hits within 12 months, with BMD dropping 6-8% at spine and up to 70% increased vertebral fracture risk.[5] Guidelines recommend 6-12 months of bisphosphonates post-Prolia to mitigate.
How Doctors Decide Extension Past 5 Years
High-risk patients (prior fractures, T-score <-3.0, glucocorticoid use) may continue up to 7-10 years if monitored quarterly for jaw pain, thigh ache, or calcium levels.[3] No universal "safe" limit exists; individualized via risk-benefit.
Prolia vs. Alternatives for Long-Term Use
Fosamax (alendronate) or Reclast (zoledronic acid) allow drug holidays after 3-5 years with lower rebound risk.[6] Prolia requires ongoing injections every 6 months, making it less ideal for indefinite use.
[1]: Prolia Prescribing Information
[2]: Cummings SR et al., JAMA 2017;317(6):603-614
[3]: Eastell R et al., J Clin Endocrinol Metab 2019;104(5):1749-1761
[4]: Khan A et al., J Bone Miner Res 2015;30(7):1242-1251
[5]: Anastasilakis AD et al., J Bone Miner Res 2017;32(12):2579-2587
[6]: Black DM et al., JAMA 2010;303(7):743-751